Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106288 · ClinicalTrials.gov registry record · Phase 3
Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia
A Phase 3 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 637
- Enrollment target
NCT00106288 is a Phase 3 study that has completed, run by Astellas Pharma. The registered enrollment target is 637 participants.
The verdict
NCT00106288, a Phase 3 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 637 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of micafungin (FK463) versus liposomal amphotericin B (AmBisome) in treating neutropenic and non-neutropenic patients with confirmed invasive candidiasis or candidemia. Enrollment will include adult and pediatric patients.
Interventions
- DRUG Micafungin
- DRUG Liposomal Amphotericin B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 637 participants |
| Start Date | 2003-01 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00106288
The ClinicalTrials.gov registry entry for NCT00106288 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 637 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Micafungin is the first listed.
NCT00106288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00106288 about?
NCT00106288 is a clinical study titled "Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia". The purpose of this study is to determine the efficacy and safety of micafungin (FK463) versus liposomal amphotericin B (AmBisome) in treating neutropenic and non-neutropenic patients with confirmed invasive candidiasis or candidemia. Enrollment will include adult and pediatric patients.
What is the current status of trial NCT00106288?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 637 participants. The study started on 2003-01. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00106288?
The interventions under investigation include: Micafungin (DRUG), Liposomal Amphotericin B (DRUG).
Who is sponsoring clinical trial NCT00106288?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.